Aspen Pharmacare Holdings Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a APNHY research report →
Companywww.aspenpharma.com
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general anesthetics, muscle relaxants, and topical agents under the Anaesthetics brand; and a range of injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors, and heparin derivatives under the Thrombosis brand.
- CEO
- Stephen Bradley Saad
- IPO
- 2010
- Employees
- 8,867
- HQ
- Durban, ZA
Price Chart
Valuation
- Market Cap
- $3.61B
- P/E
- -30.30
- P/S
- 1.57
- P/B
- 0.75
- EV/EBITDA
- 48.65
- Div Yield
- 1.55%
Profitability
- Gross Margin
- 41.91%
- Op Margin
- 16.01%
- Net Margin
- -5.19%
- ROE
- -2.41%
- ROIC
- 5.32%
Growth & Income
- Revenue
- $43.36B · -3.00%
- Net Income
- $-1,083,000,000 · -124.59%
- EPS
- $-2.44 · -124.62%
- Op Income
- $1.44B
- FCF YoY
- -84.93%
Performance & Tape
- 52W High
- $8.86
- 52W Low
- $5.24
- 50D MA
- $8.15
- 200D MA
- $6.74
- Beta
- 0.34
- Avg Volume
- 185
Get TickerSpark's AI analysis on APNHY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our APNHY Coverage
We haven't published any research on APNHY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate APNHY Report →